Resource Logo

Interleukin 1 and 2 production in homosexual men: a controlled trial of therafectin (SM-1213), a possible immunomodulator.


J Immunopharmacol. 1986;8(1):1-14. Unique Identifier : AIDSLINE

Patients with the acquired immunodeficiency syndrome (AIDS) are susceptible to a variety of opportunistic pathogens which require intact cellular immunity for control and eradication. We evaluated interleukin 1 and 2 production in 12 homosexual men without AIDS but with evidence of altered cell-mediated immunity and serologic evidence of infection with human T-cell lymphotrophic virus type III (HTLV-III), the etiologic agent of AIDS and found production of both factors diminished compared to heterosexual controls. Therafectin (SM-1213) is a new agent which selectively activates macrophages and stimulated interleukin 1 production in vitro. Therafectin was administered to these same 12 patients in a double-blind, placebo controlled trial. We failed to find any significant changes in their immunologic status including interleukin 1 or 2 production.

Acquired Immunodeficiency Syndrome/IMMUNOLOGY Adjuvants, Immunologic/THERAPEUTIC USE Clinical Trials Comparative Study Glucosamine/*ANALOGS & DERIVATIVES/IMMUNOLOGY/THERAPEUTIC USE *Homosexuality Human Immunity, Cellular/DRUG EFFECTS Interleukin-1/*METABOLISM Interleukin-2/*METABOLISM Male T-Lymphocytes, Cytotoxic/DRUG EFFECTS/IMMUNOLOGY/METABOLISM T-Lymphocytes, Helper-Inducer/DRUG EFFECTS/IMMUNOLOGY/METABOLISM CLINICAL TRIAL JOURNAL ARTICLE


Information in this article was accurate in September 30, 1986. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.